Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:HRMY NASDAQ:RZLT NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.69+1.4%$9.03$7.21▼$20.46$1.99B0.723.42 million shs2.99 million shsHRMYHarmony Biosciences$34.16+2.2%$31.63$25.52▼$40.87$1.94B0.96786,509 shs467,839 shsRZLTRezolute$4.89-5.0%$3.66$1.07▼$11.46$495.90M0.682.20 million shs1.65 million shsSTOKStoke Therapeutics$31.11+0.5%$31.79$11.17▼$40.22$1.93B1.17577,291 shs1.18 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+3.13%+0.82%+4.00%-24.36%-51.69%HRMYHarmony Biosciences+0.45%-2.19%+10.88%+23.36%+4.83%RZLTRezolute+2.59%+18.94%+58.46%+91.45%+25.30%STOKStoke Therapeutics-0.10%+3.23%+5.56%-3.76%+167.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.69+1.4%$9.03$7.21▼$20.46$1.99B0.723.42 million shs2.99 million shsHRMYHarmony Biosciences$34.16+2.2%$31.63$25.52▼$40.87$1.94B0.96786,509 shs467,839 shsRZLTRezolute$4.89-5.0%$3.66$1.07▼$11.46$495.90M0.682.20 million shs1.65 million shsSTOKStoke Therapeutics$31.11+0.5%$31.79$11.17▼$40.22$1.93B1.17577,291 shs1.18 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+3.13%+0.82%+4.00%-24.36%-51.69%HRMYHarmony Biosciences+0.45%-2.19%+10.88%+23.36%+4.83%RZLTRezolute+2.59%+18.94%+58.46%+91.45%+25.30%STOKStoke Therapeutics-0.10%+3.23%+5.56%-3.76%+167.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 2.33Hold$19.67126.31% UpsideHRMYHarmony Biosciences 2.27Hold$40.8919.70% UpsideRZLTRezolute 2.64Moderate Buy$9.3891.72% UpsideSTOKStoke Therapeutics 2.73Moderate Buy$41.8334.47% UpsideCurrent Analyst Ratings BreakdownLatest RZLT, STOK, HRMY, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026ADMAADMA Biologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/15/2026RZLTRezolute GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $11.006/10/2026ADMAADMA Biologics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy ➝ Outperform$21.006/10/2026ADMAADMA Biologics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy$21.006/3/2026RZLTRezolute Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral6/3/2026RZLTRezolute CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform6/3/2026RZLTRezolute Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$11.006/3/2026RZLTRezolute WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.00 ➝ $6.006/2/2026RZLTRezolute BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $6.006/2/2026RZLTRezolute Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $14.006/2/2026RZLTRezolute HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$510.17M3.95$0.66 per share13.10$2.01 per share4.32HRMYHarmony Biosciences$868.45M2.28$3.25 per share10.51$15.11 per share2.26RZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/ASTOKStoke Therapeutics$184.42M10.51N/AN/A$6.17 per share5.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$146.93M$0.6812.789.24N/A32.43%39.98%28.08%8/5/2026 (Estimated)HRMYHarmony Biosciences$158.69M$2.4813.779.380.2316.20%17.19%11.99%8/4/2026 (Estimated)RZLTRezolute-$74.41M-$0.82N/AN/AN/AN/A-58.82%-54.48%N/ASTOKStoke Therapeutics-$6.89M-$2.81N/AN/AN/A-529.20%-48.84%-42.27%8/11/2026 (Estimated)Latest RZLT, STOK, HRMY, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q3 2026RZLTRezolute-$0.1686-$0.16+$0.0086-$0.16N/AN/A5/7/2026Q1 2026HRMYHarmony Biosciences$0.76$0.55-$0.21$0.55$220.84 million$215.39 million5/7/2026Q1 2026STOKStoke Therapeutics-$0.80-$0.79+$0.01-$0.79$6.48 million$6.23 million5/6/2026Q1 2026ADMAADMA Biologics$0.1933$0.19-$0.0033$0.19$139.98 million$114.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.516.953.93HRMYHarmony Biosciences0.153.583.56RZLTRezoluteN/A15.8415.84STOKStoke TherapeuticsN/A8.998.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%HRMYHarmony Biosciences86.23%RZLTRezolute82.97%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.90%HRMYHarmony Biosciences11.00%RZLTRezolute14.78%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530231.77 million222.73 millionOptionableHRMYHarmony Biosciences20057.89 million51.53 millionOptionableRZLTRezolute4096.29 million82.06 millionOptionableSTOKStoke Therapeutics10062.28 million56.37 millionOptionableRZLT, STOK, HRMY, and ADMA HeadlinesRecent News About These CompaniesStoke Therapeutics (NASDAQ:STOK) General Counsel Sells $43,637.15 in StockJune 21 at 4:42 AM | americanbankingnews.comJonathan Allan Sells 1,457 Shares of Stoke Therapeutics (NASDAQ:STOK) StockJune 19, 2026 | insidertrades.comGranahan Investment Management LLC Has $6.08 Million Stock Position in Stoke Therapeutics, Inc. $STOKJune 17, 2026 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 15, 2026 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from AnalystsJune 15, 2026 | marketbeat.comRhenman & Partners Asset Management AB Lowers Position in Stoke Therapeutics, Inc. $STOKJune 13, 2026 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Trading Up 1.6% - Should You Buy?June 12, 2026 | marketbeat.comStoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.com4 Biotech Stocks Investors Should Watch in 2026June 5, 2026 | zacks.comStoke Therapeutics Stockholders Approve Directors and Governance ItemsJune 4, 2026 | tipranks.comStoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?June 4, 2026 | zacks.comBarry Ticho Sells 1,795 Shares of Stoke Therapeutics (NASDAQ:STOK) StockJune 4, 2026 | insidertrades.comStoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business UpdatesJune 1, 2026 | insidermonkey.comStoke Therapeutics to Present at Upcoming Investor Conferences in JuneMay 29, 2026 | finance.yahoo.comIs it a Good Idea to Invest in Stoke Therapeutics Stock Now?May 21, 2026 | zacks.comStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)May 18, 2026 | businesswire.comStoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent ResultsMay 12, 2026 | finance.yahoo.comStoke Therapeutics, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Guardant Health (GH) and Stoke Therapeutics (STOK)May 10, 2026 | theglobeandmail.comStoke outlines Q1 2027 rolling NDA start as EMPEROR enrollment targets June, backed by $411M cash balanceMay 8, 2026 | seekingalpha.comStoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdatesMay 8, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRZLT, STOK, HRMY, and ADMA Company DescriptionsADMA Biologics NASDAQ:ADMA$8.69 +0.12 (+1.40%) Closing price 04:00 PM EasternExtended Trading$8.62 -0.07 (-0.76%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Harmony Biosciences NASDAQ:HRMY$34.16 +0.73 (+2.18%) Closing price 04:00 PM EasternExtended Trading$34.15 -0.01 (-0.03%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Rezolute NASDAQ:RZLT$4.89 -0.26 (-5.05%) Closing price 04:00 PM EasternExtended Trading$4.89 +0.00 (+0.10%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Stoke Therapeutics NASDAQ:STOK$31.11 +0.14 (+0.45%) As of 04:00 PM EasternStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
